Hinge Health says revenue increased 50% in first quarter — still no price range for IPO

Hinge Health says revenue increased 50% in first quarter — still no price range for IPO


Hinge Health’s TrueMotion feature.

Courtesy: Hinge Health

Hinge Health on Monday updated its prospectus to include the results from its first quarter, which showed accelerating revenue growth over its fourth quarter.

The digital physical therapy startup filed to go public in March, but it has not shared a price range yet. Hinge said that revenue in its first quarter climbed 50% to $123.8 million, up from $82.7 million during the same period last year. Hinge reported $117.3 million in revenue during its fourth quarter, up 44% from the same period in 2023.

Hinge also notched its first profitable quarter on record. The company said its net income for the period was $17.1 million after taxes, up from a net loss of $26.5 million after taxes during the same period last year.

The company is attempting to go public at a time of extreme economic uncertainty and market volatility, spurred largely by President Donald Trump’s sweeping tariff policy. Several companies, including online lender Klarna and ticket marketplace StubHub, have delayed their long-awaited IPOs.

Hinge’s updated prospectus signals to investors that the company is planning to forge ahead.

More CNBC health coverage

While the company’s revenue jumped 50%, the cost of goods sold fell slightly. That allowed Hinge to lift its gross margin to 81% from 70% a year earlier and record an operating income of $13.1 million after losing $31. 4 million in the same period a year earlier.

Hinge uses software to help patients treat acute musculoskeletal injuries, chronic pain and carry out post-surgery rehabilitation remotely. Large employers cover the costs so their employees can access Hinge’s app-based virtual physical therapy, as well as its wearable electrical nerve stimulation device called Enso. 

Daniel Perez, Hinge’s CEO, and Gabriel Mecklenburg, the company’s executive chairman, co-founded the company in 2014 after experiencing personal struggles with physical rehabilitation.



Source

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Health

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

The Hers website arranged on a laptop in New York, US, on Wednesday, Feb. 12, 2025. Gabby Jones | Bloomberg | Getty Images Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk‘s patent on its branded drugs Ozempic and Wegovy is set to expire in January. “Canada is […]

Read More
Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’
Health

Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’

U.S. President Donald Trump speaks next to Defense Secretary Pete Hegseth during a cabinet meeting at the White House in Washington, D.C., U.S., July 8, 2025. Kevin Lamarque | Reuters President Donald Trump on Tuesday threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. “very soon.”  “They’re going to be tariffs […]

Read More
Healthy Returns: Medicaid cuts in Trump’s megabill may affect some drugmakers more than others
Health

Healthy Returns: Medicaid cuts in Trump’s megabill may affect some drugmakers more than others

U.S. President Donald Trump presents a sweeping spending and tax legislation, known as the “One Big Beautiful Bill Act,” after he signed it, at the White House in Washington, D.C., U.S., July 4, 2025. Leah Millis | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care […]

Read More